Loading...
Market
What will be the adoption rate of ivonescimab in NSCLC treatment by June 30, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Clinical adoption reports and surveys from healthcare analytics firms
Story
Summit’s Lung Cancer Therapy Outperforms Merck’s Keytruda by 49% in Phase 3 NSCLC Trial
Sep 8, 2024, 03:30 PM
Summit Therapeutics has announced that its lung cancer therapy, ivonescimab, has demonstrated superior efficacy compared to Merck's Keytruda in a head-to-head Phase 3 trial. The HARMONi-2 study, presented at the World Conference on Lung Cancer 2024, revealed that ivonescimab significantly reduced the risk of disease progression or death by 49% compared to Keytruda in first-line treatment of patients with PD-L1 positive advanced non-small cell lung cancer (NSCLC) in China. The trial showed a median progression-free survival (PFS) of 11.14 months for ivonescimab versus 5.82 months for Keytruda, with a hazard ratio of 0.51 and a p-value of less than 0.0001. This marks a historic first where a therapy has outperformed Keytruda in a late-stage lung cancer trial, potentially signaling a new standard of care. Akeso was involved in the trial.
View original story
Similar markets
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Yes • 50%
No • 50%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Above 55% • 25%
50-55% • 25%
45-50% • 25%
Below 45% • 25%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%